The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Promising Data for LOXO-292 in Thyroid Cancers

Lori J. Wirth, MD
Published Online:4:26 PM, Tue November 20, 2018


Lori J. Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, discusses the promising results seen so far with LOXO-292 in patients with thyroid cancer.

LOXO-292 has been well-tolerated so far with few significant adverse events (AEs). Most AEs have only been grade 1 and grade 2. The recommended dose found in the dose escalation trial is now being moved to an expansion cohort. 

For patients with RET-fusion tumors in patients with non–small cell lung cancer and differentiated thyroid cancer, the response rate has been around 77%, while patients with RET-mutated medullary thyroid cancer are experiencing a 45% response rate with this agent.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.